Longboard Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Longboard Pharmaceuticals, Maintains $60 Price Target
B. Riley Raises Price Target on Longboard Pharmaceuticals to $36 From $30, Maintains Buy Rating
Wedbush Adjusts Longboard Pharmaceuticals Price Target to $42 From $34, Maintains Outperform Rating
Longboard Pharmaceuticals Analyst Ratings
HC Wainwright & Co. : The Longboard Pharmaceuticals (LBPH.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $60.00.
HC Wainwright & Co. Reiterates Buy on Longboard Pharmaceuticals, Maintains $60 Price Target
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Longboard Pharmaceuticals (LBPH) and Travere Therapeutics (TVTX)
Buy Rating Affirmed for Longboard Pharmaceuticals Amidst Positive Clinical Progress and Market Potential for Bexicaserin
Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $60 Price Target
Wedbush Maintains Outperform on Longboard Pharmaceuticals, Raises Price Target to $34
Wedbush: The Longboard Pharmaceuticals (LBPH.US) rating was maintained, and the target price was adjusted from superior to superior market rating, and the target price was adjusted from $32.00 to $34.00.
Longboard Pharmaceuticals Analyst Ratings
Longboard Pharmaceuticals (LBPH) Receives a Buy From Wedbush
Longboard Pharmaceuticals (LBPH.US) was first covered by Baird, which gave it an superior market rating, with a target price of $36.00.
Longboard Pharmaceuticals Analyst Ratings
Baird Initiates Coverage On Longboard Pharmaceuticals With Outperform Rating, Announces Price Target of $36
Buy Rating Affirmed on Longboard Pharmaceuticals With Promising Bexicaserin Developments and Regulatory Milestones Ahead
Longboard Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Longboard Pharmaceuticals, Maintains $60 Price Target
No Data